Author response: Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022

dc.contributor.authorLucia Inchauste
dc.contributor.authorElif Nurtop
dc.contributor.authorLissete Bautista Machicado
dc.contributor.authorYanine Leigue Roth
dc.contributor.authorShirley Lenz Gonzales
dc.contributor.authorMaria Luisa Herrera
dc.contributor.authorKatty Mina Villafan
dc.contributor.authorPedro Mamani Mamani
dc.contributor.authorMarcelo Ramos Espinoza
dc.contributor.authorJuan Carlos Pavel Suarez
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:17:06Z
dc.date.available2026-03-22T21:17:06Z
dc.date.issued2025
dc.description.abstractUnlike genomic data, serological data have not been previously leveraged to evaluate the SARS-CoV-2 variants circulation. In Bolivia, sustained genomic surveillance capacities were lacking especially at the beginning of the pandemic. In 2021 and 2022 we estimated the prevalence of anti-SARS-CoV-2 antibodies in Bolivian blood donors and explored the feasibility of using virus serum neutralization data for variants thought to have circulated to map their circulation across all departments over a year-long follow-up period. Anti-S1 and anti-NCP SARS-CoV-2 IgGs were studied, along with virus neutralization tests for ancestral-D614G, Gamma, Delta, and Omicron BA.1 lineages of SARS-CoV-2. Between 2021 and 2022, the overall prevalence of anti-S1 and anti-NCP antibodies increased reaching values over 90%, demonstrating that a large proportion of the Bolivian population was no longer naïve to the virus. Viral neutralization data, analyzed through multiple approaches, revealed the spread of the Gamma variant up to 2021, particularly impacting northern departments. In 2022, Gamma continued to circulate in southernmost departments of the country and the emergence of Omicron BA.1 was detected. These trends align with publicly available genomic data from neighboring countries. Our serological analyses successfully identified both new antigenic groups, such as Omicron BA.1, and individual variants related to previously circulating groups, such as Delta. The study contributes insights into overall population immunity to SARS-CoV-2 and variant-specific immunity levels across different regions of Bolivia. It also emphasizes the potency of seroprevalence studies in informing public health decisions and underscore their value in capturing the initial phases of emerging epidemics when variant diversity is limited, facilitating timely genomic surveillance setup.
dc.identifier.doi10.7554/elife.94475.2.sa0
dc.identifier.urihttps://doi.org/10.7554/elife.94475.2.sa0
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/87026
dc.language.isoen
dc.sourceInserm
dc.subjectSerology
dc.subjectVirology
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subject2019-20 coronavirus outbreak
dc.subjectBiology
dc.subjectComputational biology
dc.subjectMedicine
dc.titleAuthor response: Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022
dc.typepeer-review

Files